SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
----------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) September 16, 2003
REPLIGEN CORPORATION
(Exact name of registration as specified in charter)
Delaware 0-14656 04-2729386
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (781) 250-0111
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Item 5. Other Events and Required FD Disclosure.
Repligen Corporation (Nasdaq: RGEN) announced on September 16, 2003 that
that it has received a Notice of Allowance from the United States Patent and
Trademark Office for a patent covering the use of CTLA4-Ig for the treatment of
rheumatoid arthritis. A press release announcing the receipt of the Notice of
Allowance is attached hereto as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
Exhibit No. Exhibit
---------- -------
99.1 Press Release dated September 16, 2003.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Repligen Corporation
Dated: September 17, 2003 By: /s/ Walter C. Herlihy
---------------------
Walter C. Herlihy
Chief Executive Officer and President
EXHIBIT INDEX
Exhibit No. Exhibit
---------- -------
99.1 Press Release dated September 16, 2003.